Literature DB >> 2136529

Cardiovascular responses to upright tilting in hypertensive patients, with and without renal impairment and before and following nisoldipine treatment.

M M Wahbha1, J Wilson, R Hainsworth.   

Abstract

1. Cardiovascular responses to upright tilting were determined before and after treatment with the calcium antagonist, nisoldipine, in patients with essential hypertension and in patients of similar ages and similar degrees of hypertension complicated by renal impairment. 2. Cardiac output was determined by a single breath respiratory method and heart rate and blood pressure by an automatic sphygmomanometer. 3. During placebo treatment, the supine values of heart rate and blood pressure were similar in the two groups, but the renal patients had significantly higher cardiac outputs. Following nisoldipine treatment blood pressure was lower in both groups due to decreased vascular resistance; cardiac output was unchanged. 4. Upright tilting lowered cardiac output in both groups, but the fall in the patients with renal disease was greater. There were similar increases in heart rate, diastolic blood pressure and vascular resistance in both groups. After nisoldipine, in the renal patients the fall in cardiac output was again greater and there was also a fall in systolic blood pressure. 5. These results indicate that patients with hypertension complicated by renal impairment may have reduced orthostatic tolerance particularly after treatment with nisoldipine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2136529      PMCID: PMC1380176          DOI: 10.1111/j.1365-2125.1990.tb03695.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Tilt test for investigating a neural component in hypertension. Its correlation with clinical characteristics.

Authors:  E D Frohlich; R C Tarazi; M Ulrych; H P Dustan; I H Page
Journal:  Circulation       Date:  1967-09       Impact factor: 29.690

2.  Diminished baroreflex sensitivity in high blood pressure.

Authors:  J D Bristow; A J Honour; G W Pickering; P Sleight; H S Smyth
Journal:  Circulation       Date:  1969-01       Impact factor: 29.690

3.  Blood volume changes and hypotension during hemodialysis.

Authors:  K E Kim; M Neff; B Cohen; M Somerstein; J Chinitz; G Onesti; C Swartz
Journal:  Trans Am Soc Artif Intern Organs       Date:  1970

4.  Cardiovascular dynamics during orthostasis and the influence of intravascular instrumentation.

Authors:  P M Stevens
Journal:  Am J Cardiol       Date:  1966-02       Impact factor: 2.778

5.  Cardiovascular and autonomic reflexes in haemodialysis patients.

Authors:  R B Naik; C J Mathias; C A Wilson; J L Reid; D J Warren
Journal:  Clin Sci (Lond)       Date:  1981-02       Impact factor: 6.124

6.  Adrenergic regulation of blood pressure in chronic renal failure.

Authors:  J J Lilley; J Golden; R A Stone
Journal:  J Clin Invest       Date:  1976-05       Impact factor: 14.808

7.  The pharmacodynamics and pharmacokinetics of a new calcium antagonist nisoldipine in normotensive and hypertensive subjects.

Authors:  F Pasanisi; P A Meredith; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Blood flow in normal and acutely ischemic myocardium after verapamil, diltiazem and nisoldipine (Bay k 5552), a new dihydropyridine calcium antagonist.

Authors:  D C Warltier; C M Meils; G J Gross; H L Brooks
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

9.  A modified single breath method for estimation of cardiac output in humans at rest and during exercise.

Authors:  Y M Al-Shamma; R Hainsworth; N P Silverton
Journal:  Clin Sci (Lond)       Date:  1987-04       Impact factor: 6.124

10.  The effect of nisoldipine on renal function in the long-term treatment of hypertension in patients with and without renal impairment.

Authors:  J Wilson; M M Wahbha; P G Martin; R Hainsworth; A M Brownjohn; J H Turney; J A Davies; C R Prentice
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.